Andrew Huberman· PhD
This was a patient with retinal degeneration, and he provided a channelrhodopsin into the eye of this patient and was able to confer some light sensitivity onto this patient that wasn't there before.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
This was a patient with retinal degeneration, and he provided a channelrhodopsin into the eye of this patient and was able to confer some light sensitivity onto this patient that wasn't there before.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
In fact, just recently, the channelopsins were applied in a human patient, to allow an adult fully blind human being to see light, for the very first time.